|
Anxiety
|
0.100 |
Biomarker
|
disease |
BEFREE |
18.3% of primary caregivers had symptoms of depression (based on PHQ-9 cut-off point of 10 or greater) while 12.7% had symptoms of anxiety (based on GAD-7 cut-off point of 10 or greater).
|
28526049 |
2017 |
|
Anxiety
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
42.5% of the patients were rated as anxiety cases (sum scores GAD-7 > 5), mean scores of anxiety showed mild to moderate symptom severity, and 43% suffered from chronic pain before surgery.
|
29587759 |
2018 |
|
Anxiety
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Anxiety and depressive symptoms were assessed with GAD-7 and PHQ-9 scales, respectively.
|
31054446 |
2019 |
|
Anxiety
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A binary logistic regression analyses were conducted to test the association between all four ratings in GAD-7 (anxiety) and PHQ-9 (depression) scales subitems as covariates, and migraine vs no headache as the outcome.
|
28324317 |
2017 |
|
Anxiety
|
0.100 |
Biomarker
|
disease |
BEFREE |
A previous study showed that knockdown of Gad1 from NPY+ cells led to reduced anxiety behaviors in adult mice.
|
30024942 |
2018 |
|
Anxiety
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A total of 34% reported either a prior diagnosis of depression or scored 10 or greater on the PHQ-8, and 31% reported either a prior diagnosis of anxiety or scored 10 or greater on the GAD-7.
|
30637564 |
2019 |
|
Anxiety
|
0.100 |
Biomarker
|
disease |
BEFREE |
After completing the 4-week treatment program, patients showed significant improvements in depressed mood (t=3.642, p=0.001) based on the Patient Health Questionnaire-9 (PHQ-9), anxiety (t=3.198, p=0.003) based on the Generalized Anxiety Disorder seven-item (GAD-7) scale, and PTSD symptoms (t=5.363, p<0.001) based on the Posttraumatic Stress Disorder Check List (PCL).
|
30380815 |
2018 |
|
Anxiety
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among 200 participants (male, 77.3%; female, 22.8%), 54% had PHQ-9 and 52% had GAD-7 scores indicating moderate to severe depression or anxiety without diagnosis of either disorder.
|
31571840 |
2019 |
|
Anxiety
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among 2100 participants (1051 males and 1049 females), 475 (22.6%) were identified with anxiety (scoring 8 points or higher on the GAD-7 scale).
|
30125814 |
2018 |
|
Anxiety
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Based on ICIQ-OAB scores, patients were dichotomized as having OAB versus LUTS-other, and GAD-7 scores categorized patients as having anxiety.
|
31302716 |
2019 |
|
Anxiety
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Data were collected by using a pre-developed questionnaire, consisting of socio-demographic information, comprehensive lifestyle information, and psychological health information including a nine-item scale, the Patient Health Questionnaire-9 (PHQ-9) for assessing the level of depression, and a 7-item scale, the Generalized Anxiety Disorder-7 (GAD-7) for assessing the level of anxiety.
|
31226611 |
2019 |
|
Anxiety
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Emotional processing theory variables did not predict any anxiety outcomes at posttreatment or follow-up with one exception: Initial fear activation predicted less anxiety at follow-up among youth without GAD.
|
27355694 |
2019 |
|
Anxiety
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, self-rating questionnaires were used to assess somatic symptom severity (PHQ-15), depression severity (PHQ-9) and anxiety severity (GAD-7).
|
28554368 |
2017 |
|
Anxiety
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hearing performance was assessed with Freiburg monosyllabic test and Oldenburg inventory (OI); the health-related quality of life was measured with Nijmegen Cochlear Implantation Questionnaire (NCIQ); depressive symptoms with General Depression Scale (ADS-L); stress with Perceived Stress Questionnaire (PSQ) and anxiety with General Anxiety Disorder-7 (GAD-7).
|
30870379 |
2019 |
|
Anxiety
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunostaining in the basolateral amygdala (BLA) for GAD, a marker for GABA, at the end of the behavioral testing showed the late decrease in anxiety behavior was correlated with upregulation of inhibition.
|
30728770 |
2019 |
|
Anxiety
|
0.100 |
Biomarker
|
disease |
BEFREE |
In a cross-sectional study, 23 patients with IPF were evaluated using Montreal Cognitive Assessment (MoCA), an instrument for detecting mild cognitive impairments and were screened for OSA through overnight cardiorespiratory polygraphy and for anxiety and depression with three specific scale (Generalized Anxiety Disorder 7-item scale: GAD-7; the Patient Health Questionnaire: PHQ-9; Hospital Anxiety and Depression Scale: HADS).
|
30707735 |
2019 |
|
Anxiety
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this pilot study, nineteen female students participating on a NCAA Division III athletic team (hockey="in-season"; soccer="off-season") were compared for level of fitness (modified Balke test of VO<sub>2</sub> max), salivary IgA levels by immunoassay, anxiety (using a GAD-7 survey), salivary cortisol levels by immunoassay, and numbers of culturable bacteria by growth of CFU/ml on blood agar, mitis salivarius agar and Staphylococcus 110 agar.
|
27932242 |
2017 |
|
Anxiety
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this single-centre approach, n = 1,000 adolescents will be screened (using PHQ-9 and GAD-7), and adolescents with results indicative of anxiety or depressive symptoms (n = 162) will be advised to seek psychological health care in clusters from treating physicians in specialised outpatient departments.
|
30428891 |
2018 |
|
Anxiety
|
0.100 |
Biomarker
|
disease |
BEFREE |
Item response theory-based linking methods were used to create crosswalk tables that convert scores on the GAD-7 to the TBI-QOL Anxiety metric and scores on the PHQ-9 to the TBI-QOL Depression metric.
|
31498233 |
2019 |
|
Anxiety
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Measures included PHQ-9 (depression), GAD-7 (anxiety) and PCL-C (post-traumatic stress disorder).
|
30591033 |
2018 |
|
Anxiety
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Of the 208 patients included in the study, 29 patients (13.9%) were positive for moderate-to-severe depression (PHQ-9 ≥ 10) and 22 patients (10.6%) were positive for anxiety (GAD-7 ≥ 10) symptoms.
|
30293440 |
2019 |
|
Anxiety
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Of the 36 women who started iCBT, 26 completed all three lessons of treatment (76% adherence rate). iCBT produced moderate to large effect size reductions for anxiety on the GAD-7 (Hedges' g = 0.76) and psychological distress on the Kessler-10 (g = 0.88) that were superior to TAU.
|
30266030 |
2019 |
|
Anxiety
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study offers preliminary evidence for use of the PSWQ-A and GAD-7 for assessment of anxiety in a sample of low-income, predominantly African American participants.
|
30810345 |
2020 |
|
Anxiety
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Participants were also screened for depression using the Neurological Disorder Depression Inventory for Epilepsy (NDDI-E) and the Center for Epidemiologic Studies Depression Scale (CES-D) and for anxiety using the Generalized Anxiety Disorder-7 (GAD-7) scale.
|
31181426 |
2019 |
|
Anxiety
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Participants with RA completed the Patient Health Questionnaire (PHQ-2, PHQ-9), Patient Reported Outcomes Measurement Information System Depression Short Form-8a (PROMIS Depression) and Anxiety Short Form-8a (PROMIS Anxiety), Hospital Anxiety and Depression Scale anxiety score (HADS-A) and depression score (HADS-D), Overall Anxiety Severity and Impairment Scale (OASIS), Generalized Anxiety Disorder-2 and 7 item scales (GAD-2, GAD-7) and Kessler-6 scale.
|
31199570 |
2019 |